Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 Pandemic.
Vicente Aldasoro CáceresMaría Laíño PiñeiroBerta IbáñezMónica Enguita GermánPublished in: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2022)
Mass switch from IV to subcutaneous TCZ during the SARS-CoV-2 pandemic has been safe, effective, and well tolerated after 1 year of follow-up.